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A b s t r a c t  A series of 417 consecutively admitted psychi- 
atric inpatients were studied with regard to their use of po- 
tentially abusive psychotropic substances in the last 3 
months preceding admission. In all patients face-to-face 
interviews were performed; in 354 of them urine speci- 
mens could also be tested. Alcohol and benzodiazepines 
belonged to the most frequently used substances followed 
by cannabis, opiates and cocaine. Barbiturates, hallucino- 
gens and amphetamine derivatives were only exception- 
ally reported. The most important finding of the study is 
that every fifth patient regularly used "hard" drugs (opi- 
ates and/or cocaine), every fourth patient illegal drugs and 
every third patient alcohol. Substances were found in 54% 
of all urine specimens; methadone, opiates and cocaine 
were hardly found alone. For the latter substances excel- 
lent agreement was found between interview reports and 
urine exams. Excluding patients diagnosed as substance- 
use disorders, there were no statistically significant differ- 
ences between schizophrenic, affective, neurotic/stress/ 
somatoform and other disorders with regard to the use of 
"hard" drugs and illegal drugs. Regular substance use cor- 
related with much worse psychosocial adjustment. Sub- 
stance use has to be explored and considered in every in- 
dividual psychiatric inpatient. 
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Introduction 
Higher prevalence rates of substance-use disorder have 
been found among psychiatric patients than in the general 
population (Group for the Advancement of Psychiatry 
J. Modestin (tg~). C. Nussbanmer. K. Angst - P. Scheidegger 
D. Hell 
Psychiatric University Hospital Zurich, Lenggstrasse 31, 
CH-8029 Zurich, Switzerland 
1991) or in other comparison groups; e.g. in a series of 
300 psychiatric patients 62% of men and 48% of women 
qualified as heavy users of some substance of abuse in- 
cluding alcohol, this proportion being more than twice as 
high as that found in medical and surgical patients (Davis 
1984). Dual patients more frequently are male, suffer 
from personality disorders and have legal problems 
(Lehman et al. 1993). They also present more serious 
symptoms, increased utilization of treatment resources 
and are more likely to have a mood disorder (Ries et al. 
1994) than patients with mental disorders without psy- 
choactive substance use disorder. Dual patients, however, 
represent a heterogeneous population (Lehman et al. 1994 
c); half of them have no independent mental disorder but 
suffer from psychiatric syndromes related to drug abuse; 
preferential drugs of abuse of the latter group are opiates, 
cocaine and hallucinogens (Lehman et al. 1994 a). In con- 
trast, drug-abusing patients with independent axis-I men- 
tal disorders more likely use alcohol and cannabis, and 
their drug use problems are generally less severe (Leh- 
mann et al. 1994b, 1994c). In Table 1 a survey is given of 
studies mostly performed on narrowly defined samples of 
severely ill psychotic patients and investigating preva- 
lence of abuse with regard to particular substances of 
abuse. 
The importance of drug abuse in axis-I mental disor- 
ders has abundantly been demonstrated in schizophrenia. 
Drugs may play a precipitating role in the development of 
the disorder (Andrrasson et al. 1987, 1989), they can 
mimic or augment psychotic symptoms, precipitate re- 
lapse and affect outcome (Treffert 1978; Turner and 
Tsuang 1990; Swofford et al. 1996). Drug-abusing and 
drug-free schizophrenic patients differ in various ways: 
schizophrenic drug abusers experience symptoms earlier 
(Breakey et al. 1974) and seem to have better premorbid 
personality and psychosocial adjustment (Arndt et al. 
1992; Breaky et al. 1974; Buckley et al. 1994). In some 
schizophrenic patients drugs lead to a transient symptom 
reduction (Dixon et al. 1990), and in others to more severe 
positive symptoms (Negrete et al. 1986). Drug-abusing 
psychotic patients have a higher readmission rate (Gupta 
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Table 1 Prevalence of abuse (%) by particular substance of abuse in different samples of psychiatric patients. 
Authors Substance abuse Population/ n Alco- Coca- Amphe- Sedatives/ Canna- Hallu- Opia- 
definition mental disorder hol ine tamine Hypnotics bis cinogens tes 
Mueser et al. 1992 Lifetime history Schizophrenic disorder 85 45 
of abuse/dependence Schizoaffective disorder 74 42 
Major depression 47 47 
Bipolar disorder 41 66 
Estroff et al. 1985 Lifetime drug abuse Bipolar disorder 36 67 
Dixon et al. 1991 DSM-III-R diagnosis Schizophrenic/ 83 25 
drug abuse/dependence schizoaffective disorder 
Mueser et al. 1990 Lifetime substance Schizophrenic/schizo- 149 47 
abuse affective/schizo- 
phreniform disorder 
Barbee et al. 1989 Lifetime substance Schizophrenic disorder 53 47 4 
abuse/dependence 
Siris et al. 1988  History of RDC Schizophrenic/schizo- 46 13 
substance abuse affective disorder with 
postpsychotic depression 
Barry et al. 1995 Lifetime drug problems Chronically mentally ill 253 39 2 
Lehman et al. 1993 Current DSM-III-R Consecutively admitted 274 43 23 
Lehmann et al. psychoactive psychiatric inpatients 435 39 17 
1994 a substance-use disorder 
Soyka et al. 1993 3-month prevalence Consecutively admitted 447 71 20 
of drug abuse schizophrenic inpatients 
Brady et al. 1991 Current or past Consecutively admitted 100 68 
substance abuse psychiatric inpatients 
Miller et al. 1989 DSM-III-R drug abuse Consecutively admitted 
schizophrenic males 50 24 16 
bipolar patients 60 18 10 
29 14 7 22 8 9 
17 10 8 8 15 15 
36 20 11 11 2 11 
29 21 20 22 10 10 
39 39 31 b 64 31 25 
17 6 4 31 6 0 
25 a 7 42 18 4 
11 9 b 36 6 8 
13 4 35 11 2 
3 2 b 16 0 2 
< 1 1 14 4 12 
< 1  1 11 3 8 
14 22 b 43 26 16 
17 a 4 7 3 1 
4 4 26 2 0 
3 3 8 0 5 
a Stimulants including cocaine 
b Benzodiazepines only 
et al. 1996), show re la t ive  neu ro l ep t i c  r e f rac to r iness  
(Bowers  et al. 1990), h igher  rate o f  therapy compl ica t ions  
(Dixon  et al. 1992) and a typical  course o f  i l lness  charac-  
ter ized by  the change  f rom the p redominance  of  negat ive  
to a p redominance  o f  pos i t ive  symptoms  (Rosenthal  et al. 
1994). They  were  repor ted  to be at an increased  r isk of  be-  
having  v io lent ly  (Smith and Hucker  1994) and o f  a t tempt-  
ing suicide (Soyka  et al. 1993). The  comorb id i ty  o f  schiz- 
ophrenia  and substance-use  d i sorder  is c la imed  to be best  
exp la ined  by  the vulnerabi l i ty  model :  drugs lead to psy-  
chot ic  b reakdown  in suscept ible  popula t ion  (Newm a n  and 
Mi l le r  1992). Accord ing ly ,  many  schizophrenic  dual  pa-  
t ients started their  drug abuse before  the onset  of  schizo-  
phrenia  (Si lver  and A b b o u d  1994), even though this has 
not  been  conf i rmed  in other  studies (Soyka  et al. 1993; 
Hek imian  and Gershon  1968). 
It is not only mentally ill people who abuse drugs fre- 
quently; reversely, high prevalence rates of  psychiatric dis- 
orders have been found among patients with substance- 
abuse problems (Group for the Advancement  of  Psychiatry 
1991). For  example,  among 350 drug-dependent  inpatients 
37% met the criteria for axis-I psychiatric disorders other 
than substance abuse (Mirin et al. 1991). Axis- I  disorders 
most frequently found in drug-dependent  patients are affec- 
tive disorders, anxiety disorders and antisocial personali ty 
disorder (Mirin et al. 1991; Kokkevi  and Stefanis 1995; 
Brady and Sonne 1995; Walker  et al. 1994; Ross et al. 1988). 
The  present  s tudy inves t iga ted  f requency of  psy-  
chotropic  substance use in a sample  of  pat ients  f rom a ge- 
ographica l ly  def ined  ca tchment  area who were  consecu-  
t ively referred and admit ted  for inpat ient  t reatment.  Urine  
analyses  were  inc luded to test the re l iabi l i ty  o f  the pa-  
t ients '  in terview reports.  The s tudy also a imed  at compar -  
ing ind iv idua l  d iagnost ic  subgroups  with each other  with 
regard  to the rates of  substance use. 
Methods 
The study was performed during a 4-month period (June to Octo- 
ber 1994) at the Psychiatric University Hospital Zurich. The hos- 
pital provides full inpatient care for all inhabitants of the catch- 
ment area. Basically, no patient who needs psychiatric hospitaliza- 
tion can be refused and patients of all diagnostic categories are ad- 
mitted. All consecutive admissions younger than 65 years of age 
were included in the study. All patients were given a short semi- 
structured interview; the answers of the patients were noted on a 
self-prepared questionnaire. The individual items of the question- 
naire were derived from the German version of the European Ad- 
diction Severity Index (Gsellhofer et al. 1993) and from the West- 
minster Substance Use Questionnaire (Adelekan et al. 1994). The 
questions concerned sociodemographic and some clinical data as 
well as data on substance use. The vast majority of the interviews 
were carried out by one of the authors (C.N.) during the first 2 
days of the patients' hospitalization after an informed consent had 
been obtained. In a small proportion of the patients the clinical 
condition did not allow interviews at such an early point of time. 
These patients were approached later during their hospital stay. 
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Additional sociodemographic and clinical data including diag- 
noses were obtained from the clinical admission and discharge 
files. 
Sociodemographic data studied included gender, age, marital 
status, family status, nationality, place of residence, school educa- 
tion, professional apprenticeship, different forms of living situa- 
tion before index admission, financial resources before index ad- 
mission, debts, criminal and aggressive behavior in the last week 
preceding index admission, punishments because of violations of 
drug law, violations of other laws and driving while intoxicated. 
Clinical data included certification of the patient, duration of index 
hospitalization, regular/irregular discharge, different modalities of 
living situation after discharge, status as smoker/non-smoker, in- 
travenous use of drugs in the past and ICD-10 diagnoses. Regard- 
ing substance use, as precise information as was possible was col- 
lected including the kind of substances and the frequency of their 
use in the last 3 months preceding index admission. Five cate- 
gories of substance-use frequency were built (never, less than once 
a week, once to twice a week, three and more times a week and 
daily use); for the purpose of the statistical evaluation, however, 
only three categories were considered including (a) no use (never 
taken substances in the study period), (b) sporadic use (twice a 
week or less) and (c) regular use (three times a week or more). The 
corresponding groups of patients are called (a) substance non- 
users, (b) sporadic substance users and (c) regular substance users. 
Separately, the frequency of substance use in the last 2 days pre- 
ceding admission was also asked in the interviews. 
In order to verify the interview reports of the patients with re- 
gard to their very recent substance use, urine tests were performed 
within 48 h after admission, on the condition that the patients 
agreed with the urine drug screen. The urine screens included the 
following substances: benzodiazepines, barbiturates, cannabis, 
hallucinogens, amphetamine derivatives, methadone, other opiates 
(including heroin) and cocaine. 
The results were evaluated using non-parametric ~2 test for cat- 
egorical and Kruskal-Wallis test for continuous variables. To test 
the agreement between interview reports and urine screens kappa 
coefficients were calculated. Due to the higher number of compar- 
isons performed, the Bonferroni correction for multiple compar- 
isons was introduced in the tables. 
Results 
In the course o f  the 4 -month  s tudy per iod  a total  566 pa-  
t ients were  consecut ive ly  admi t ted  to the hospital .  Of  
them, 77 d id  not  fulfil  the age cri terion.  In 71 o f  the re- 
main ing  489 patients no in terview was possible :  20 pa-  
t ients refused the interview, 5 pat ients  did  not  unders tand 
German,  34 could  not be in te rv iewed because  of  their  im- 
media te  d ischarge  and in 12 the interview was not  poss i -  
b le  because  of  their  longer- las t ing  thought  disorder.  Al to -  
gether  418 pat ients  could  be in teviewed;  however ,  1 pa-  
t ient refused to answer  the quest ions about  his substance 
use so that  417 pat ients  were  inc luded in the study. A few 
of  them refused to answer  some other  quest ions which  ex-  
plains  differ ing "n"  in ind iv idua l  i tems.  In 63 of  the inter- 
v i ewed  pat ients  no urine screen could  be per formed,  in 
the major i ty  of  them because  of  their  refusal  to give the 
urine specimen.  On the other  hand, 21 urine spec imens  
(not cons idered  further in this study) were avai lab le  f rom 
the pat ients  who could  not  be interviewed.  In 354 pat ients  
a full  set o f  data  inc luding repor t  on drug use and urine 
screen was avai lable .  
The sample  of  417 pat ients  was c o m p o s e d  of  240 men  
with an average age of  38 years  (SD + 11 years)  and o f  
177 w o m e n  with an average age of  40 years  (SD + 12 
years).  In Table 2 results  o f  the in terview reports  on sub- 
stance use in the last 3 months  in these 417 consecut ive ly  
admi t ted  psychia t r ic  pat ients  are given,  d iv id ing  the sam- 
ple  into three groups def ined  above:  substance non-users ,  
sporadic  users and regular  users. As  can be seen, barbi tu-  
rates,  ha l luc inogens  and amphe tamine  der ivat ives  were  
only  except iona l ly  used. Alcoho l  and benzodiazep ines ,  
but  also cannabis ,  opiates  inc luding methadone  and co-  
caine,  were  used frequently.  One third o f  the pat ients  used 
a lcohol  regularly,  one fourth i l legal  drugs and one fifth 
"hard"  i l legal  drugs (and methadone) .  
In Table 3 the three groups o f  non-users ,  sporadic  users 
and regular  users o f  i l legal  drugs (def ined by  their  drug 
use in the last  3 months  preceding  admiss ion)  are com-  
pared  with regard  to some demograph ic ,  social  and clini-  
cal var iables .  Only  s ignif icant  di f ferences  are indicated.  
C o m p a r e d  with the non-users  the regular  users o f  i l legal  
Table 2 Interview reports on substance use (3- month prevalence) in 417 consecutively admitted psychiatric inpatients. Presented are 
numbers of patients who did not use (non-users), rarely used (sporadic users) and frequently used (regular users) individual substances 
indicated on the left. Percentages are given in parentheses. 
Total (n) Substance Sporadic substance users Regular substance users 
non-users (never) (< 2 times/week) (> 3 times/week) 
1. Alcohol 417 
2. Benzodiazepines 414 
3. Barbiturates 415 
4. Cannabis 417 
5. Hallucinogens 417 
6. Amphetamine derivatives including ecstasy 417 
7. Methadone 417 
8. Heroin 417 
9. Other opiates 417 
10. Cocaine 417 
"Hard drugs" (7-10) 417 
Illegal drugs including methadone (4-10) 417 
Polysubstance use (> 2 substances/day) 416 
(100) 115 (28) 169 (41) 133 (32) 
(100) 228 (55) 65 (16) 121 (29) 
(100) 406 (98) 3 (< 1) 6 (1) 
(100) 318 (76) 47 (11) 52 (12) 
(100) 413 (99) 4 (1) 0 (0) 
(100) 410 (98) 6 (1) 1 (< 1) 
(100) 351 (84) 5 (1) 61 (15) 
(100) 335 (80) 20 (5) 62 (15) 
(100) 403 (97) 9 (2) 5 (1) 
(100) 338 (81) 29 (7) 50 (12) 
(100) 316 (76) 21 (5) 80 (19) 
(100) 276 (66) 37 (9) 104 (25) 
(100) 251 (60) 54 (13) 111 (27) 
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Table 3 Comparison of non-users, sporadic users and regular users of illegal drugs (including methadone) with regard to some demo- 
graphic, social and clinical variables. Percentages are given in parentheses. 
Illegal-drug Illegal-drug Illegal-drug Significance 
non-users sporadic users regular users (df = 2) 
nl = 276 (100) n2 = 37 (100) n 3 = 104 (100) 
)~2 p 
Gender: men 145 (53) 26 (70) 
Age (years): mean + SD 43 + 11 32 + 8 
Marital status: single 127 (46) 28 (76) 
Non-Swiss nationality 56 (20) 7 (19) 
Basic education only 63 (23) 9 (24) 
Gainfully occupied 135 (49) 19 (51) 
On welfare 39 (14) 10 (27) 
Disability pension 111 (40) 10 (27) 
Illegal revenues/prostitution 0 (0) 2 (5) 
Debts (> 1000 SFr) a 52 (19) 17 (46) 
Criminal behaviour in the last week 8 (3) 4 (11) 
Punishments because of drug law violations 7 (3) 10 (27) 
Punishments because of other law violations 53 (19) 16 (43) 
Smoker 186 (67) 32 (86) 
(Past) intravenous use of drugs 8 (3) 12 (32) 
Duration of index hospitalization (days): mean + SD 30 + 31 26 + 33 
Irregular discharge b 7 (3) 0 (0) 
ICD- 10 diagnoses c 
F10 Alcohol-use disorders 80 (29) 3 (8) 
F1 Other substance-use disorders 8 (3) 14 (38) 
F2 Schizophrenic disorders 102 (37) 18 (49) 
F3 Affective disorders 67 (24) 4 (11) 
F4 Neurotic/stress/somatoform disorders 42 (15) 4 (11) 
Others 50 (18) 6 (16) 
69 (66) 8.58 0.014 
30 + 7 114.02 < 0.0001 d 
87 (84) 49.13 < 0.0001 ~ 
7 (7) 10.07 0.006 
47 (45) 18.71 < 0.0001 d 
20 (19) 28.92 < 0.0001 d 
48 (46) 43.72 < 0.0001 d 
22 (21) 13.13 0.0014 
21 (20) 59.10 < 0.0001 d 
53 (51) 43.60 < 0.0001 ~ 
60 (58) 159.01 < 0.0001 d 
66 (63) 177.17 < 0.0001 d 
54 (52) 42.58 < 0.0001 d 
102 (98) 42.01 < 0.0001 d 
60 (58) 150.87 < 0.0001 a 
19 + 18 8.47 0.014 
9 (9) 8.27 0.016 
6 (6) 23.64 < 0.0001 d 
86 (83) 253.62 < 0.0001 ~ 
24 (23) 10.01 0.007 
15 (14) 6.87 0.032 
5 (5) 7.70 0.021 
16 (15) n.s. 
an 1 = 275, n 3 = 103 for this variable 
b n !  = 242, n2 = 34, n3 = 99 for this variable 
c Each patient could be given more than one diagnosis 
d Remains significant using Bonferroni correction for multiple 
comparisons (p < 0.0013) 
drugs were  more  f requent ly  young,  s ingle men  o f  Swiss  
nat ionali ty.  They  were  less wel l  educated,  had less fre- 
quent ly  pa id  jobs  and rece ived  less f requent ly  a d isabi l i ty  
pension.  On the other  hand, they l ived more  f requent ly  
f rom welfare  or f rom i l legal  revenues,  had debts  and were  
much  more  f requent ly  cr iminal  because  o f  v iola t ions  o f  
drug and other  laws. They  s tayed in the hospi tal  for  a 
shorter  t ime and were  more  f requent ly  i r regular ly  dis-  
charged.  They  were  more  f requent ly  d iagnosed  as sub- 
s tance-use disorders  (other  than a lcohol)  and rece ived  less 
f requent ly  the d iagnos is  of  a l coho l i sm and schizophrenic ,  
affect ive and neuro t ic / s t ress / somatoform disorders .  Spo-  
radic  users of  i l legal  drugs stand in many  respects  be-  
tween these two groups;  their  demograph ic  character is t ics  
were more  s imi lar  to those o f  regular  users. On the other  
hand, in some social  var iables  and in terms of  d iagnost ic  
dis t r ibut ion they more  r e sembled  the group o f  non-users .  
In 354 patients drug urine tests could  be carried out and 
compared  with the interview data. In 163 (46%) no sub- 
stances were found; in contrast,  in 89 (25%) more than one 
substance was identified. As  indicated in Table 4 benzodi-  
azepines were identif ied in 142 (40%) of  354 urine speci- 
mens,  fo l lowed by opiates  (68 = 19%), cocaine (51 = 
15%), methadone  (43 = 12%) and cannabis (36 = 10%). 
Whereas  in 56% of  benzodiazepine-pos i t ive  urine speci- 
mens no other substances were found, i l legal  drugs and 
methadone  - detected al together  in 27% of  the specimens - 
were rarely found alone. Opiates alone were found in only 
6 of  68 opiate-posi t ive  specimens,  cocaine in 2 of  51 
cocaine-posi t ive  specimens and methadone in 1 of  43 
methadone-pos i t ive  specimens.  Cannabis  alone was identi-  
fied in 10 of  36 cannabis-posi t ive  specimens.  No patient in- 
dicated the use of  amphetamine derivat ives or hal lucino-  
gens (LSD) in the interview; accordingly,  these substances 
were never  found in urine tests. Furthermore,  in Table 4 the 
degree of  agreement  between the interview reports (regard- 
ing substance use in the last 2 days before admiss ion)  and 
the urine exam results is indicated by kappa  coefficients.  
Excel lent  agreement  was found for opiates,  methadone  and 
cocaine,  and fair to relat ively good agreement  in the case of  
benzodiazepines ,  barbiturates and cannabis.  
Final ly,  Table 5 compares  in terview reports  on the spo- 
radic  and regula r  substance use (prevalence  in the last 3 
months  preceding  index admiss ion)  in the six ma in  d iag-  
nost ic  categories .  Regard ing  sporadic  substance use, alco- 
hol ics  used less f requent ly  and pat ients  with other  sub- 
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Table 4 Substance use in the last 2 days before admission. Comparison of the interview data with the results of urine exams (n = 354). 
Percentages are given in parentheses. 
Substance use in the last 2 days before admission (interview reports): 
Benzodiazepines Barbiturates Cannabis Methadone Opiates Cocaine 
Yes No Yes No Yes No Yes No Yes No Yes No 
Substance use Yes 81 (23) 61 (17) 6(2) 15 (4) 21 (6) 15 (4) 37(10) 6 (2) 61 (17) 7 (2) 42(12) 9 (3) 
(positive No 39 (11) 172 (49) 0 (0) 333 (94) 17 (5) 301 (85) 9 (3) 301 (85) 4 (1) 282 (80) 8 (2) 295 (83) 
urine exams) 
Kappa 0.40 0.43 0.52 0.81 0.90 0.80 
Table 5 Interview reports on sporadic and regular substance use (3-month prevalence) in the main diagnostic categories. Each patient 
could be given more than one diagnosis. Percentages are given in parentheses. 
F10 F1 (without F2 F3 F4 
Alcohol-use F10) Schizophrenic Affective Neurotic, stress 
disorders Other disorders disorders and somatoform 
substance- disorders 
use disorders 
n 89 (100) 108 (100) 144 (100) 86 (100) 51 (100) 
Other Significance 
disorders (df= 5) 
72 (100) ~2 p 
Sporadic substance use (< 2 times~week) 
Alcohol 25 (28) 39 (36) 69 (48) 36 (42) 22 (43) 
Benzodiazepines 15 (17) 22 (20) 15 (10) 18 (21) 4 (8) 
Cannabis 2 (2) 30 (28) 17 (12) 4 (5) 3 (6) 
"Hard" drugs (opiates, cocaine) 1 (1) 14 (13) 8 (6) 4 (5) 2 (4) 
Illegal drugs including methadone 3 (3) 14 (13) 18 (12) 4 (5) 4 (8) 
Polysubstance use 12 (13) 15 (14) 20 (14) 14 (16) 7 (14) 
(< 2 substances/day) 
Regular substance use (< 3 times~week) 
Alcohol 56 (63) 40 (37) 27 (19) 19 (22) 10 (20) 
Benzodiazepines 22 (25) 50 (46) 23 (16) 30 (35) 22 (43) 
Cannabis 4 (4) 37 (34) 17 (12) 8 (9) 1 (2) 
"Hard" drugs (opiates, cocaine) 2 (2) 76 (65) 12 (8) 8 (9) 5 (10) 
Illegal drugs including methadone 6 (7) 86 (80) 24 (17) 15 (17) 5 (10) 
Polysubstance use 20 (22) 80 (74) 17 (12) 16 (19) 8 (16) 
(> 2 substances/day) 
26 (36) 10.47 0.063 
11 (15) n.s. 
7 (10) 41.53 < 0.0001 a 
4 (6) 13.78 0.017 
6 (8) 9.86 0.079 
7 (10) n.s. 
27 (37) 59.86 < 0.0001 a 
23 (32) 32.86 < 0.0001 a 
10 (14) 51.79 <0.0001 a 
10 (14) 207.87 < 0.0001 a 
16 (22) 187.72 < 0.0001 a 
18 (25) 138.80 < 0.0001 a 
aRemains significant using Bonferroni correction for multiple comparisons (p < 0.0014) 
s tance-use  d i sorders  more  f requent ly  cannabis  and "hard"  
drugs;  bes ides ,  no rea l ly  impor tan t  d i f ferences  exis t  be-  
tween  the d iagnos t ic  subgroups .  More  h igh ly  s ignif icant  
d i f ferences  were  found  wi th  regard  to regula r  subs tance  
use. As  could  be expec ted ,  a h igher  p ropor t ion  o f  a lco-  
hol ics  regular ly  used  a lcohol  and a h igher  p ropor t ion  of  
pat ients  in the ca tegory  o f  o ther  subs tance-use  d isorders  
regular ly  used other  subs tances  o f  all  k inds.  Repea t ing  
the compar i sons  under  exc lus ion  o f  the lat ter  d iagnos t ic  
subgroup  the p ropor t ion  o f  regu la r  benzod iazep ine  users  
was s igni f icant ly  sma l l e r  in the subgroup  o f  schizo-  
phrenic  d isorders  and s ign i f ican t ly  fewer  pat ients  with al-  
cohol -use  d i sorder  regu la r ly  used  "hard"  and i l legal  
drugs.  There  were  no s igni f icant  d i f ferences  be tween  
schizophrenic ,  affect ive,  neuro t i c / s t r ess / somatoform and 
other  d i sorders  wi th  regard  to the use  of  "ha rd"  drugs  and 
i l legal  drugs.  
Discussion 
We inves t iga ted  substance use in a consecut ive  series of  
psychia t r ic  pat ients  referred for  hospi ta l iza t ion.  The  vast  
major i ty  of  the admit ted  pat ients  par t ic ipa ted  in the s tudy 
interviews;  the propor t ion  of  rea l ly  refusing subjects  
amounted  to only 4%. We conf ined  our  explora t ion  
strictly to the f requency o f  the substance use; thus, we 
avo ided  the p rob lem of  the def ini t ion o f  substance use, 
abuse and dependence .  Also ,  we d id  not  inquire  about  the 
amount  of  the drugs taken,  as we d id  not  expec t  to rece ive  
re l iable  data  in this regard.  We s tudied 3-month  preva-  
lence o f  substance use; thus, our  data  are bas ica l ly  cross  
sectional .  However ,  the propor t ion  of  drug abusers  among  
menta l ly  ill  pat ients  does  not  seem to change  dur ing a me-  
d ium- te rm fo l low-up (Bartels  et al. 1995), even  though 
f luctuat ions in the rate o f  abuse o f  ind iv idua l  substances  
are being observed  (Baberg et al. 1996) depend ing  on the 
d rugs '  avai labi l i ty  (e l -Gueba ly  1975). 
The 3-month prevalence of the regular alcohol use in 
our study was found to be 32%, a proportion which seems 
to be lower than in the majority of studies indicated in 
Table 1; however, most of those studies investigated life- 
time prevalence and we applied a narrow definition of 
regular substance use. Almost the same proportion of our 
patients (29%) regularly used benzodiazepines. The regu- 
lar benzodiazepine use was especially high in the sub- 
group of neurotic/stress/somatoform disorders, where it 
was almost as high as in the subgroup of substance-use 
disorders other than alcohol (43 vs 46%). Of course, in 
some patients benzodiazepines (especially when found in 
urine alone) will have been used therapeutically; in others 
they probably were abused - benzodiazepines were hardly 
medically prescribed to more than half of all patients with 
substance-use disorders. Barbiturates, amphetamine de- 
rivatives including ecstasy and hallucinogens were only 
exceptionally reported and seem to play practically no 
role in our inpatient population at present. In contrast, one 
third of our patients used cannabis, half of them regularly. 
This contradicts the observation that abuse of stimulants, 
hallucinogens and cannabis are related to each other 
(Mueser et al. 1990). Corresponding frequencies of 
cannabis use/abuse were found in other studies mostly in- 
vestigating patients of specific diagnostic samples (com- 
pare Table 1). Excluding the subgroup of substance-use 
disorders other than alcohol, there were no significant dif- 
ferences between our diagnostic categories including 
schizophrenic disorders and alcoholism with regard to 
cannabis use. 
Altogether, 15% of our patients used regularly, and an 
additional 5% sporadically, heroin; 12% of all our patients 
used regularly, and another 7% sporadically, cocaine. 
Whereas the use of cocaine in our population seems to 
correspond to that reported in other studies, the proportion 
of our patients using opiates belongs to the highest re- 
ported in the literature. This high proportion may be due 
to the presence of patients with substance-use disorders in 
our study sample, encompassing all consecutive psychi- 
atric hospital admissions. Incidentally, excluding sub- 
stance-use disorders, there were no significant differences 
between the remaining diagnostic subgroups with regard 
to the use of "hard" or illegal drugs. Specific drugs of 
choice have been shown to differ by diagnosis: psychotic 
(Tsuang 1982) and especially schizophrenic patients' 
(Schneier and Siris 1987) use of amphetamine, cocaine 
and hallucinogens was said to be greater (or equal), and 
their use of alcohol, opiates and sedative hypnotics less 
(or equal) than use by control groups consisting of other 
psychiatric patients or normal subjects (Mueser et al. 
1990). We were not able to confirm these findings of more 
or less preferential use of stimulants, cocaine or other sub- 
stances we studied by schizophrenic in comparison with 
other patients, specifically with patients suffering from af- 
fective disorders and neurotic/stress/somatoform disorders. 
In only a minority of other studies were urine drug 
tests included. Self-reports identified more opiate and co- 
caine use than random urine screens (Zanis et al. 1994), 
false-negative screens having been found in almost half of 
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the patients acknowledging drug use (Appleby et al. 
1995). On the other hand, half of the schizophrenic pa- 
tients and 45% of psychotic patients, respectively, with 
positive urine drug screens denied drug use in self-reports 
(Shaner et al. 1993; Brady et al. 1991). Positive drug 
screens were found in 39% of patients at the psychiatric 
emergency room and in 35% of patients of the psychiatric 
intensive treatment unit (Sanguineti and Samuel 1993). 
The proportion of positive urine tests (at least one sub- 
stance) in our study was 54%. Generally, the interview re- 
ports by our patients were confirmed by the results of 
urine specimens. An only fair to relatively good agree- 
ment was found in the case of benzodiazepines, barbitu- 
rates and cannabis. This result, however, does not neces- 
sarily indicate incorrectness of the patients' interview 
data. All these substances can be - partially due to their 
longer half-times, partially due to their kind of body dis- 
tribution - excreted in the urine for days after the last sub- 
stance intake. We compared the findings of the urine ex- 
ams with the reports of substance intake in the last 2 days. 
Some patients may have used substances earlier and were 
still excreting them in urine. Regarding methadone, opi- 
ates and cocaine, excellent agreement was found. This 
finding underlines the correctness of the patients' reports 
and indicates indirectly the high validity of our results 
with regard to the prevalence of substance use in our pop- 
ulation, all the more because only 15% of the interviewed 
patients refused urine exams. 
As could be expected, the three patient groups, namely 
the non-users, the sporadic users and the regular users of 
illegal drugs, differed significantly from each other in 
many social, demographic and clinical aspects. The most 
pronounced differences were, of course, found between 
the non-users and the regular users, the latter group being 
different not only in the demographic characteristics, but 
equally so in their psychosocial adjustment including fi- 
nancial revenues and criminal behaviour. Clearly, the 
more frequent the (illegal) substance use, the less success- 
ful and independent is the overall psychosocial adjust- 
ment. A total of 23% of illegal-drug (including metha- 
done) regular users received the diagnosis of schizo- 
phrenic disorder; a subgroup of these patients used "hard" 
drugs. Whereas schizophrenic patients using cannabis 
have been extensively studied, this has unfortunately not 
been the case regarding the existing group of schizo- 
phrenic users of "hard" drugs. 
Our results confirm that substance use represents a 
very frequent event in the population of patients referred 
for psychiatric admission at present. Altogether, almost 
every fifth of our patients regularly used "hard" drugs 
(opiates and/or cocaine), every fourth illegal drugs and 
every third alcohol, which thus remains the "substance 
number one". In the majority of our patients polysub- 
stance use was identified and this finding was substanti- 
ated by the results of urine exams: e.g. cocaine alone was 
found in only 2 of 51 cocaine-positive and methadone in 
only 1 of 43 methadone-positive urine specimens. Basi- 
cally, in patients of all diagnostic subgroups some sub- 
stance use was identified, although to different extents: 
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e.g. the proport ion of i l legal-drug users was 55% among 
substance-use disorders, 29% among schizophrenic disor- 
ders, 22% among affective disorders and 18% among neu-  
rotic/stress/somatoform disorders. As ment ioned  previ- 
ously, in the literature considerable attention has been 
paid to the substance use of schizophrenic patients. In 
contrast, patients of other diagnostic categories, such as 
affective disorders, have only exceptionally been studied 
in this respect (Estroff et al. 1985; Miller  et al. 1989; 
Mueser  et al. 1992; Kales et al. 1995). Our results indicate 
that this neglect  is not just if ied because - except for sub- 
stance-use disorders - the use of  different substances is 
not  significantly more frequent  in the category of schizo- 
phrenic than in other disorders ( including affective disor- 
ders). 
The clinical implicat ions of our and other studies '  f ind- 
ings are clear: individuals  with mental  disorders are al- 
most  three t imes more likely to have some addictive dis- 
order than individuals  without mental  disorders (Regier et 
al. 1990) and substance use is frequent in patients seeking 
psychiatric treatment (Sheehan 1993). As quoted in the 
introduction,  it can inf luence the occurrence, form, course 
and outcome of mental  disorders of different kinds. 
Therefore, in mental  patients of all diagnostic categories 
the question of substance use has to be explored and the 
f indings have to be properly evaluated and taken into con- 
sideration in the diagnostic as well as in the therapeutic 
process. 
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